Bharat Immunologicals Share Price Today | Stock Price & Bharat Immunologicals Share Screener
As of October 5, 2026, the live Bharat Immunologicals share price (BSE: BIBCL) is ₹7.53, down 7.95% from the previous close, with shares trading between ₹7.42 and ₹8.04 in today's trading session, and a 52-week range of ₹7.53–₹21.95. Check BIBCL 52-week performance for the annual price range and momentum. Use the Bharat Immunologicals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Bharat Immunologicals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹9 and net income of ₹-18, with EBITDA of ₹-17, an operating margin of -13.0% and a profit margin of -200.0%.
Bharat Immunologicals Share Price Chart
Track the current stock price of Bharat Immunologicals with an interactive chart. Analyse BIBCL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Bharat Immunologicals stock quote in one place.
The quote of ₹7.53 sits between the 52-week low of ₹7.53 and the 52-week high of ₹21.95, and the latest session moved -7.95% from the previous close.
Bharat Immunologicals Company Profile - Fundamental Screener
Screen Bharat Immunologicals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BIBCL shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE994B01014.
Company Details
Classification
Identifiers and Leadership
Bharat Immunologicals Balance Sheet Screener
Screen BIBCL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2023, total assets were ₹186, down from ₹213 in 2022.
Latest statistics put total assets at ₹186 and shareholder funds at ₹88.
| Item | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
Assets |
|||||||||
| Total Assets | 186 | 213 | 104 | 127 | 125 | 53 | 59 | 68 | 80 |
| Current Assets | 33 | 65 | 34 | 93 | 99 | 38 | 47 | 60 | 74 |
| Fixed Assets | 115 | 116 | 4 | 5 | 5 | 5 | 5 | 6 | 6 |
Liabilities |
|||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 6 | 6 | 6 | 6 | 6 | 3 | 3 | 3 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||||
| Total Equity | 88 | 105 | 34 | 21 | 31 | 38 | 42 | 35 | 41 |
| Share Capital | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| Reserves & Surplus | 45 | 62 | -9 | -23 | -13 | -6 | -1 | -8 | -2 |
Bharat Immunologicals Income Statement Screener - Profit & Revenue Analysis
Screen Bharat Immunologicals income statement and profit fundamentals. Analyze BIBCL quarterly results. Bharat Immunologicals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹9 and net profit was ₹-18, equal to earnings per unit of ₹-4.20, at an operating margin of -13%.
In that period expenses were ₹25, interest cost ₹8 and tax ₹0. The next period listed, 2023-March, shows revenue of ₹47 and net profit of ₹-17.
| Item | None-None | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||||
| Revenue | 9 | 47 | 80 | 87 | 68 | 88 | 36 | 125 | 129 | 147 |
| Expenses | 25 | 63 | 83 | 106 | 77 | 93 | 43 | 112 | 133 | 143 |
Operating Costs and Margins | ||||||||||
| EBITDA | -17 | -16 | -4 | -19 | -9 | -5 | -7 | 14 | -4 | 4 |
| Operating Profit % | -13.00% | -41.00% | -6.00% | -24.00% | -16.00% | -11.00% | -24.00% | 10.00% | -4.00% | 2.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Interest | 8 | 7 | 6 | 5 | 5 | 2 | 1 | 4 | 5 | 1 |
Profit and Earnings | ||||||||||
| Profit Before Tax | -25 | -23 | -10 | -24 | -14 | -7 | -8 | 9 | -9 | 2 |
| Tax | 0 | -6 | -1 | -6 | -4 | -2 | -4 | 3 | -3 | 1 |
| Net Profit | -18 | -17 | -9 | -18 | -10 | -6 | -4 | 7 | -6 | 2 |
| EPS | -4.20 | -3.95 | -2.03 | 1.10 | -2.36 | -1.34 | -0.99 | 1.51 | -1.44 | 0.36 |
Bharat Immunologicals Cash Flow Screener - Liquidity Fundamentals
Screen BIBCL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2023-March, operating activities generated ₹11, and net cash flow was an outflow of ₹3.
Over the same period, investing activities provided ₹1 and financing activities used ₹15.
| Item | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | |||||||||
| Operating Activities | 11 | -42 | 12 | 34 | -32 | 3 | -17 | -9 | 8 |
| Investing Activities | 1 | 1 | 1 | 1 | 1 | -1 | 1 | 1 | 0 |
Financing and Net Cash | |||||||||
| Financing Activities | -15 | 45 | -12 | -34 | 31 | -1 | -3 | -2 | -1 |
| Net Cash Flow | -3 | 3 | 0 | 1 | -1 | 1 | -20 | -10 | 7 |
Bharat Immunologicals Shareholding Pattern Screener
See Bharat Immunologicals shareholding pattern with promoter, FII, and DII holdings. Check Bharat Immunologicals promoter holding and ownership changes for BIBCL on TickJournal, and see how institutional stock price moves affect the market.
In 2024-Mar, promoters held 59.25%, foreign institutions 0.00%, domestic institutions 0.00% and the public 39.47%, spread across 35,313 shareholders.
The shareholder count was 35,313 in 2024-Mar, compared with 35,535 in 2023-Mar.
| Item | 2024-Mar | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 39.47% | 38.97% | 39.13% | 39.30% | 39.35% | 38.77% | 39.15% | 39.11% |
| Other Holding | 1.28% | 1.77% | 1.61% | 1.45% | 1.39% | 1.97% | 1.59% | 1.63% |
| Shareholder Count | 35,313 | 35,535 | 34,818 | 34,201 | 34,910 | 36,323 | 35,695 | 35,411 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Bharat Immunologicals. Bharat Immunologicals dividend yield can be compared with peers and other stocks in the market.
Bharat Immunologicals Stock Index Membership - Nifty & Sensex
See which indices include Bharat Immunologicals stock. Check BIBCL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 1 indices, including BSE INDEX CPSE.
Complete Index List
Bharat Immunologicals Market Events Screener - Corporate Actions
Get Bharat Immunologicals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Bharat Immunologicals stock events that may affect BIBCL share price, along with derivatives, futures and options activity and sector gainers.
1 corporate actions are listed, the most recent entry being Annual General Meeting dated December 29, 2023, with a record date of December 29, 2023.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2023-12-29 | 2023-12-29 | Annual General Meeting | NA | 39.59% |
Bharat Immunologicals Competitors Screener - Peer Stocks Comparison
Screen BIBCL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Bharat Immunologicals Company Announcements - News & Reports Screener
Screen BIBCL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated September 17, 2026 and August 7, 2024.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Clarification sought from Bharat Immunologicals & Biologicals Corporation Ltd | - |
| 2026-09-17 | Announcement under Regulation 30 (LODR)-Winding-up | - |
| 2024-08-07 | Board Meeting Intimation for Intimation Of Date Of Board Meeting On 16.08.2024 Under Regulation 29 Of SEBI'S LODR. | - |
| 2024-02-29 | Board Meeting Intimation for Intimation Of Date Of Board Meeting On 08.03.2024 Under Regulation 29 Of SEBI'S LODR. | - |
| 2023-12-13 | Compliance Of Regulation 34 Of LODR 2015 And Submission Annual Report For 34Th Annual General Meeting Scheduled On 29.12.2023. | - |
| 2023-11-28 | Compliance Of The Regulation Of LODR 2015 For The Intimation Of Book Closure Period (22.12.2023 To 29.12.2023) Of The Company In Respect Of 34Th Annual General Meeting Scheduled To Be Held On 29.12.2023. | - |
| 2023-11-28 | Submission Of Notice Of 34Th Annual General Meeting On 29.12.2023 As Compliance Of The Provision Of LODR 2015. | - |
| 2023-11-01 | Submission Of Unaudited Quarterly Financial Results Alongwith Limited Review Report For The Quarter And Half Year Ended September 2023 As Compliance Of LODR 2015 | - |
| 2023-11-01 | Submission Of Unaudited Quarterly Financial Results Alongwith Limited Review Report For The Quarter Ended June 2023 As Compliance Of LODR 2015 | - |
| 2023-10-19 | Board Meeting Intimation for Intimation Of Date Of Board Meeting On 31St October 2023 Under Regulation 29 Of SEBI'S LODR. | - |
| 2023-09-15 | Submission Of Signed Audited Annual Accounts 2022-23 Alongwith Statutory Audit Report Thereof Provided By The Statutory Auditor Appointed By Comptroller & Auditor General Of India (C&AG). | - |
| 2023-05-31 | Submission Of Annual Accounts For The Financial Year Ended On 31.03.2023 And Is Under Audit Of Statutory Auditor Appointed By C&AG | - |
| 2023-05-10 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2023-05-10 | Compliance Certificate Under Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ending On 31.03.2023. | - |
| 2023-04-27 | Certificate From Practicing Company Secretary Under Regulation 40 (9) Of SEBI (LODR) Regulations 2015 For The Year Ended 31.03.2023 | - |
| 2023-04-17 | Update on board meeting | - |
| 2023-04-17 | Board Meeting Intimation for Intimation Of Date Of Board Meeting On 17Th April 2023 Under Regulation 29 Of SEBI'S LODR. | - |
| 2023-02-10 | Submission Of Unaudited Quarterly Financial Results For The Quarter And Nine Months Ended December 2022 Along With Limited Review Report | - |
| 2023-02-01 | Board Meeting Intimation for Intimation Of Date Of Board Meeting On 09Th February 2023 Under Regulation 29 Of SEBI'S LODR. | - |
| 2022-12-27 | Clarification sought from Bharat Immunologicals & Biologicals Corporation Ltd | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹7.53, within a 52-week range of ₹7.53 to ₹21.95. The P/E ratio is -2.17 and the P/B ratio is -1.20, with earnings per unit of ₹-3.95. Market capitalisation stands at ₹35.30 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 9 balance sheet periods, 10 income statement periods, 9 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.